If you have been reading about DMSO stock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-27. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Buoyancy force = weight of object in empty space − weight of object immersed in fluid The final result would be measured in Newtons. Air's density is very small compared to most solids and liquids. For this reason, the weight of an object in air is approximately the same as its true weight in a vacuum. The buoyancy of air is neglected for most objects during a measurement in air because the error is usually insignificant (typically less than 0.1% except for objects of very low average density such as a balloon or light foam).
On 23 May 2013, Essendon CEO Ian Robson resigned, agreeing with the Switkowski report's assessment that a lack of proper process had occurred in 2012. In late July, Essendon chairman David Evans resigned due to health concerns, and was replaced by deputy chairman Paul Little, who had served on the board since 2011. At the same time as Essendon was being investigated, the Cronulla-Sutherland Sharks club from the National Rugby League was also under investigation for its 2011 supplements program. Stephen Dank was a common factor, as he had been employed at Cronulla as a sports scientist during that program; he was later banned for life from involvement in rugby league for his role in that program.
Islamic scholars have diverse opinions on the obligatory nature of male circumcision, with some considering it mandatory (wājib), while others view it as only being recommended (sunnah). According to historians of religion and scholars of religious studies, the Islamic tradition of circumcision was derived from the Pagan practices and rituals of pre-Islamic Arabia. Although there is some debate within Islam over whether it is a religious requirement or mere recommendation, circumcision (called khitan) is practiced nearly universally by Muslim males. Islam bases its practice of circumcision on the Genesis 17 narrative, the same Biblical chapter referred to by Jews. The procedure is not explicitly mentioned in the Quran, however, it is a tradition established by Islam's prophet Muhammad directly (following Abraham), and so its practice is considered a sunnah (prophet's tradition) and is very important in Islam. For Muslims, circumcision is also a matter of cleanliness, purification and control over one's baser self (nafs). There is no agreement across the many Islamic communities about the age at which circumcision should be performed. It may be done from soon after birth up to about age 15; most often it is performed at around six to seven years of age. The timing can correspond with the boy's completion of his recitation of the whole Quran, with a coming-of-age event such as taking on the responsibility of daily prayer or betrothal. Circumcision may be celebrated with an associated family or community event.
Sources: en.wikipedia.org
The use of psilocybin mushrooms in religious ceremonies dating back thousands of years is contested. Despite popular narratives portraying psychedelics as ancient, widespread, and primarily used by shamans for therapeutic healing, anthropological and historical research shows their traditional use was limited, recent, and culturally specific, with modern Western interpretations largely shaped by idealization, tourism, and ideological agendas. Reliable evidence shows that psilocybin mushrooms were used ritualistically in pre-Columbian Mexico but were otherwise rare, with most claims of ancient widespread use exaggerated or misinterpreted. It has been argued that the Tassili Mushroom Figure, discovered in Tassili, Algeria, is evidence of an early psilocybin-containing mushroom cult. 6,000-year-old pictographs discovered near Villar del Humo, Spain, illustrate several mushrooms that have been argued to be Psilocybe hispanica, a hallucinogenic species native to the area. Some scholars have also interpreted archaeological artifacts from Mexico and the so-called Mayan "mushroom stones" of Guatemala as evidence of ritual and ceremonial use of psychoactive mushrooms in the Mayan and Aztec cultures. After Spanish conquistadors of the New World arrived in the 16th century, chroniclers reported mushroom use by the natives for ceremonial and religious purposes. According to the Dominican friar Diego Durán in The History of the Indies of New Spain (published c.
In 2005, he introduced an algorithm for computing the absolute partitioning free energies of unfolded peptides into the phosphatidylcholine bilayer interface. In his studies, he also described how partitioning of membrane-active oligopeptides into membrane interfaces plays a significant role in terms of promoting the formation of secondary structure. Focusing on the partitioning of two series of small model peptides into the interfaces of neutral (zwitterionic) phospholipid membranes, he determined a complete interfacial hydrophobicity scale that includes the contribution of the peptide bond. His study with von Heijne based on the recognition of transmembrane helices by the endoplasmic reticulum translocon introduced a new dimension to the problem of predicting transmembrane helices from amino acid sequences, as well as showing that direct protein–lipid interactions are critical during translocon-mediated membrane insertion. White studied the preference of tryptophan and tyrosine residues for membrane interfaces as significant features of membrane proteins. He explored several possibilities for tryptophan's interfacial preference. Most recently, his lab developed methods for studying membrane protein biogenesis and folding in E. coli using chimeric single-span membrane proteins. White was part of a consortium of scientists that developed a comprehensive classification system for lipids.
=== Multi-Stream Transport (MST) === Multi-Stream Transport is a feature first introduced in the DisplayPort 1.2 standard. It allows multiple independent displays to be driven from a single DP port on the source devices by multiplexing several video streams into a single stream and sending it to a branch device, which demultiplexes the signal into the original streams. Branch devices are commonly found in the form of an MST hub, which plugs into a single DP input port and provides multiple outputs, but it can also be implemented on a display internally to provide a DP output port for daisy-chaining, effectively embedding a 2-port MST hub inside the display. Theoretically, up to 63 displays can be supported, but the combined data rate requirements of all the displays cannot exceed the limits of a single DP port (17.28 Gbit/s for a DP 1.2 port, or 25.92 Gbit/s for a DP 1.3/1.4 port). In addition, the maximum number of links between the source and any device (i.e. the maximum length of a daisy-chain) is 7, and the maximum number of physical output ports on each branch device (such as a hub) is 7. With the release of MST, standard single-display operation has been retroactively named "SST" mode (Single-Stream Transport). Daisy-chaining is a feature that must be specifically supported by each intermediary display; not all DisplayPort 1.2 devices support it. Daisy-chaining requires a dedicated DisplayPort output port on the display. Standard DisplayPort input ports found on most displays cannot be used as a daisy-chain output.
It is accepted practice to assume that if any symptom typical of DCS is present, that the diver has DCS and will be treated accordingly with recompression. Limited case data suggest that recompression does not usually cause harm if the differential diagnosis between IEBt vs IEDCS is doubtful.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.